Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene

被引:335
作者
Ghigna, C
Giordano, S
Shen, HH
Benvenuto, F
Castiglioni, F
Comoglio, PM
Green, MR
Riva, S
Biamonti, G
机构
[1] CNR, Ist Genet Mol, I-27100 Pavia, Italy
[2] Inst Canc Res & Treatment, I-10060 Candiolo, Torino, Italy
[3] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA
[4] Policlin San Matteo, IRCCS, I-27100 Pavia, Italy
[5] Ist Nazl Tumori, I-20133 Milan, Italy
关键词
D O I
10.1016/j.molcel.2005.10.026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ron, the tyrosine kinase receptor for the Macrophage-stimulating protein, is involved in cell dissociation, motility, and matrix invasion. Delta Ron, a constitutively active isoform that confers increased motility to expressing cells, is generated through the skipping of exon 11. We show that abnormal accumulation of Delta Ron mRNA occurs in breast and colon tumors. Skipping of exon 11 is controlled by a silencer and an enhancer of splicing located in the constitutive exon 12. The strength of the enhancer parallels the relative abundance of A Ron mRNA and depends on a sequence directly bound by splicing factor SF2/ASF. Overexpression and RNAi experiments demonstrate that SF2/ASF, by controlling the production of Delta Ron, activates epithelial to mesenchymal transition leading to cell locomotion. The effect of SF2/ASF overexpression is reverted by specific knockdown of Delta Ron mRNA. This demonstrates a direct link between SF2/ASF-regulated splicing and cell motility, an activity important for embryogenesis, tissue formation, and tumor metastasis.
引用
收藏
页码:881 / 890
页数:10
相关论文
共 38 条
[11]   A PROTEIN FACTOR, ASF, CONTROLS CELL-SPECIFIC ALTERNATIVE SPLICING OF SV40 EARLY PRE-MESSENGER-RNA INVITRO [J].
GE, H ;
MANLEY, JL .
CELL, 1990, 62 (01) :25-34
[12]  
Ghigna C, 1998, CANCER RES, V58, P5818
[13]  
Hanamura A, 1998, RNA, V4, P430
[14]   SRprises along a messenger's journey [J].
Huang, YQ ;
Steitz, JA .
MOLECULAR CELL, 2005, 17 (05) :613-615
[15]  
ITOH H, 1994, CANCER RES, V54, P3237
[16]   Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays [J].
Johnson, JM ;
Castle, J ;
Garrett-Engele, P ;
Kan, ZY ;
Loerch, PM ;
Armour, CD ;
Santos, R ;
Schadt, EE ;
Stoughton, R ;
Shoemaker, DD .
SCIENCE, 2003, 302 (5653) :2141-2144
[17]   Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors [J].
Jordan, P ;
Brazao, R ;
Boavida, MG ;
Gespach, C ;
Chastre, E .
ONCOGENE, 1999, 18 (48) :6835-6839
[18]   The splicing factor SRp20 modifies splicing of its own mRNA and ASF/SF2 antagonizes this regulation [J].
Jumaa, H ;
Nielsen, PJ .
EMBO JOURNAL, 1997, 16 (16) :5077-5085
[19]   Pre-mRNA splicing of IgM exons M1 and M2 is directed by a juxtaposed splicing enhancer and inhibitor [J].
Kan, JLC ;
Green, MR .
GENES & DEVELOPMENT, 1999, 13 (04) :462-471
[20]   A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy [J].
Kashima, T ;
Manley, JL .
NATURE GENETICS, 2003, 34 (04) :460-463